KR101380568B1 - Novel use of extract of Pogongyeong - Google Patents
Novel use of extract of Pogongyeong Download PDFInfo
- Publication number
- KR101380568B1 KR101380568B1 KR1020120045772A KR20120045772A KR101380568B1 KR 101380568 B1 KR101380568 B1 KR 101380568B1 KR 1020120045772 A KR1020120045772 A KR 1020120045772A KR 20120045772 A KR20120045772 A KR 20120045772A KR 101380568 B1 KR101380568 B1 KR 101380568B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- disease
- pogongyoung
- food
- forgetfulness
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 69
- 206010027175 memory impairment Diseases 0.000 claims abstract description 34
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 235000013361 beverage Nutrition 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 abstract description 36
- 230000003412 degenerative effect Effects 0.000 abstract description 34
- 238000011282 treatment Methods 0.000 abstract description 17
- 230000002265 prevention Effects 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 19
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 19
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 19
- 229960002646 scopolamine Drugs 0.000 description 19
- 206010012289 Dementia Diseases 0.000 description 18
- 208000006011 Stroke Diseases 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 102000012440 Acetylcholinesterase Human genes 0.000 description 15
- 108010022752 Acetylcholinesterase Proteins 0.000 description 15
- 229940022698 acetylcholinesterase Drugs 0.000 description 15
- 230000006872 improvement Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 208000024827 Alzheimer disease Diseases 0.000 description 12
- 208000000044 Amnesia Diseases 0.000 description 11
- 208000026139 Memory disease Diseases 0.000 description 10
- 208000010877 cognitive disease Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000006984 memory degeneration Effects 0.000 description 10
- 208000023060 memory loss Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 208000028698 Cognitive impairment Diseases 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 230000013016 learning Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 8
- 229960001685 tacrine Drugs 0.000 description 8
- 208000023105 Huntington disease Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000006993 memory improvement Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 238000012347 Morris Water Maze Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940005213 tacrine 10 mg Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- 229960001499 neostigmine bromide Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229940124206 Nicotine inhibitor Drugs 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 241001272081 Taraxacum coreanum Species 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 241000691199 Taraxacum platycarpum Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- MOYZEMOPQDTDHA-UHFFFAOYSA-N norscopolamine Natural products C1C(C2OC22)NC2CC1OC(=O)C(CO)C1=CC=CC=C1 MOYZEMOPQDTDHA-UHFFFAOYSA-N 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 포공영 추출물의 건망증 또는 퇴행성 뇌질환 중 어느 하나의 치료, 개선 및/또는 예방을 위한 의약 및/또는 식품 용도를 제공한다. 본 발명에 의해 건망증 또는 퇴행성 뇌질환 중 어느 하나를 효과적으로 치료, 개선 및/또는 예방할 수 있다는 장점이 있다.The present invention provides a medicament and / or food use for the treatment, amelioration and / or prevention of either forgetfulness or degenerative brain disease of pogongyoung extract. The present invention has the advantage of being able to effectively treat, ameliorate and / or prevent either forgetfulness or degenerative brain disease.
Description
본 발명은 포공영 추출물의 신규 용도에 관한 것으로, 보다 상세하게는 포공영 추출물의 신규 의약 또는 식품 용도에 관한 것이다. The present invention relates to a novel use of pogongyoung extract, and more particularly to a new pharmaceutical or food use of poongong extract.
기억인지력의 장애를 겪는 건망증은 인간의 평균수명이 증가하는 현대 사회에서 특히 중요한 관심의 대상이 되고 있다.Forgetfulness with memory-cognitive impairments is of particular interest in modern societies, where the average life expectancy of humans increases.
이와 같은 건망증과 함께 기억인지력의 장애가 문제되는 퇴행성 뇌질환으로는 뇌졸중, 중풍, 치매, 알츠하이머 질환, 파킨슨 질환, 또는 헌팅턴 질환 등이 있다.Degenerative brain diseases in which memory impairment is a problem with forgetfulness include stroke, stroke, dementia, Alzheimer's disease, Parkinson's disease, or Huntington's disease.
상기 치매는 일반적으로 다양한 원인에 의해 뇌기능이 손상되면서 인지기능이 지속적이고 전반적으로 저하되어 일상, 사회생활을 영위하는데 어려움을 겪게 되는 상태를 말한다. 인지 기능이란 기억력, 언어 능력, 시공간 파악 능력, 판단력 및 추상적 사고력 등 다양한 지적 능력을 가르키는 것으로 각 인지기능은 특정 뇌 부위와 밀접한 관련이 있다. 치매의 원인으로는 퇴행성 뇌질환인 알츠하이머병(Alzheimer's Disease)이나 파킨슨병(Parkinson's Disease)에서부터 뇌출혈, 대사성질환인 간성뇌병증, 윌슨병(Wilson's Disease), 감염성 질환인 신경매독, 후천성면역결핍증, 알코올과 같은 약물중독, 뇌외상 등 다양한 병인이 있으며, 어떤 형태로든 중추신경계에 구조적, 기능적 이상을 초래할 수 있는 질환은 치매를 유발할 수가 있다. The dementia generally refers to a condition in which brain function is impaired by various causes and cognitive function is continuously and generally degraded, thereby making it difficult to manage daily and social life. Cognitive function refers to a variety of intellectual skills such as memory, language ability, space-time grasping ability, judgment ability and abstract thinking ability. Each cognitive function is closely related to a specific brain region. The causes of dementia include Alzheimer's disease and Parkinson's disease, degenerative brain diseases, hemorrhagic encephalopathy, metabolic diseases, hepatic encephalopathy, Wilson's disease, infectious neuropathy, acquired immunodeficiency, alcohol and alcohol. There are various etiologies, such as drug addiction and brain trauma, and diseases that can cause structural and functional abnormalities in the central nervous system in some form can cause dementia.
알츠하이머형 치매(Alzheimerdisease)는 치매를 일으키는 가장 흔한 퇴행성 뇌질환으로, 노인인구에서 치매를 유발하는 가장 흔한 원인이며, 65세 이상의 치매 환자 중 50~60%가 알츠하이머형 치매로 알려져 있다. 이 질병은 매우 서서히 발병하여 점진적으로 진행되는 경과가 특징적이다. 초기에는 주로 최근 일에 대한 기억력에서 문제를 보이다가 진행하면서 언어기능이나 판단력 등 다른 여러 인지기능의 이상을 동반하게 되다가 결국에는 모든 일상생활 기능을 상실하게 된다. 알츠하이머병은 그 진행과정에서 인지기능 저하뿐만 아니라 성격변화, 초조행동, 우울증, 망상, 환각, 공격성 증가, 수면 장애 등의 정신행동 증상이 흔히 동반되며 말기에 이르면 경직, 보행 이상 등의 신경학적 장애 또는 대소변 실금, 감염, 욕창 등 신체적인 합병증까지 나타나게 된다. 치매는 그 장기간의 치료를 요하는 점과 그 증상의 특성 때문에 생활 불편 정도가 암과 같은 다른 중증 질환보다도 심하며, 환자의 관리와 보호에 드는 신체적, 심리적, 경제적 부담 또한 매우 크다. 노년인구의 급속한 증가속도와 치매 유병률 추이로 미루어 볼 때, 치매는 사회적, 국가적 해결책이 필요한 과제임이 분명하다. Alzheimer's dementia is the most common degenerative brain disease that causes dementia, the most common cause of dementia in the elderly population, and 50-60% of dementia patients older than 65 years are known as Alzheimer's dementia. The disease develops very slowly and is characterized by a progressive course. In the early stages, they usually showed problems in their memory of recent work, accompanied by abnormalities of language and judgment, and other cognitive functions, and eventually lost all daily life functions. Alzheimer's disease is often accompanied by mental behavioral symptoms such as personality changes, nervousness, depression, delusions, hallucinations, increased aggression, sleep disorders, and neurological disorders such as stiffness and gait abnormalities. Or physical complications such as faeces, incontinence, infections, and pressure sores. Dementia has a longer life discomfort than other serious diseases such as cancer because of its long-term treatment and the nature of its symptoms, and the physical, psychological and economic burden of managing and protecting patients is also very high. Given the rapid growth of the elderly population and the prevalence of dementia, it is clear that dementia is a challenge that requires social and national solutions.
지금까지의 대표적 퇴행성 뇌질환인 치매 연구는 주로 뇌 콜린성 신경세포의 광범위한 변성 및 소실이 인지능 감퇴의 주요 원으로 생각되어, 남아있는 콜린성 신경계의 활성을 증가시켜 손상된 인지능을 부분적으로나 회복시킬 수 있는 약물들에 관한 연구가 주로 진행되었다. 현재까지 치매 치료제로 개발된 약물에는 아세틸콜린 (acetylcholine) 합성 전구체로 레시틴, 수용체 활성제로 RS-86, 니코틴, 아세틸콜린 분해 효소 억제제 (acetylcholinesterase inhibitor; AchE inhibitor)로 Pfizer/Eisai 사의 아리셉트 (Aricept), First Horizon 사의 코그넥스 (Cognex), Norvatis 사의 엑실론 (Exelon), Janssen 사의 레미닐 (Reminyl) 등이 있다. 이 약물들은 아세틸콜린이라고 하는 신경 전달 물질의 분해를 막아 주어, 감퇴된 인지 기능을 개선시켜 주는 효과를 가지고 있지만, 효과는 일시적이고 미약하며, 심각한 독성 있는 경우가 존재하여 아직 사용에는 논란의 여지가 많은 상태이다.The dementia research, a representative degenerative brain disease so far, is thought to be the main source of cognitive decline mainly due to extensive degeneration and loss of brain cholinergic neurons, which can partially restore the damaged cognitive ability by increasing the activity of the remaining cholinergic nervous system. Most studies have been carried out on drugs. Drugs that have been developed to treat dementia so far include lecithin as an acetylcholine synthetic precursor, RS-86 as a receptor activator, nicotine, and acetylcholinesterase inhibitor (AchE inhibitor) as Aricept from Pfizer / Eisai, Cognex from First Horizon, Exelon from Norvatis, and Reminyl from Janssen. These drugs have the effect of preventing the breakdown of neurotransmitters called acetylcholine, which improves cognitive decline, but the effects are temporary, mild, and seriously toxic. There are many states.
따라서, 기억인지력의 장애를 수반하는 건망증과 퇴행성 뇌질환의 치료, 개선 또는 예방 기술의 개발이 시급한 실정이다.Therefore, there is an urgent need to develop techniques for the treatment, improvement or prevention of forgetfulness and degenerative brain diseases involving memory cognitive impairment.
한편, 포공영(蒲公英)은 대한약전외한약(생약)규격집에 수재되어 있는 생약으로, 포공영 추출물이 간질환 치료 및 예방에 효과적임이 알려져 있다(대한민국 공개특허 제10-2004-0076106호 참조). On the other hand, Pogongyoung (蒲公英) is a herbal medicine that is stored in the Korean herbal medicine (Herbal Medicine) standard collection, it is known that pogongyoung extract is effective in the treatment and prevention of liver disease (see Republic of Korea Patent Publication No. 10-2004-0076106).
본 발명이 해결하고자 하는 과제는 건망증 또는 퇴행성 뇌질환의 치료, 개선 또는 예방에 효과를 나타내는 물질의 신규 용도를 제공하는 것이다.The problem to be solved by the present invention is to provide a novel use of the material that is effective in the treatment, improvement or prevention of forgetfulness or degenerative brain disease.
본 발명의 과제는 상기에 언급된 과제로 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The object of the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.
발명자들은 놀랍게도 포공영(蒲公英) 추출물이 스코폴라민에 의해 유도된 건망증동물의 학습증진 및 공간지각능력의 회복이 우수함을 확인하여, 포공영 추출물이 건망증 또는 퇴행성 뇌질환의 치료, 개선 및/또는 예방에 효과를 나타냄을 알게 되어 본 발명을 완성하였다. The inventors have surprisingly found that pogongyoung extract is excellent in improving learning and spatial perception ability of amnesia induced by scopolamine, so that poongong extract is effective in the treatment, improvement and / or prevention of forgetfulness or degenerative brain disease. It was found that the effect was completed to complete the present invention.
본 발명은 포공영 추출물의 건망증 또는 퇴행성 뇌질환 중 어느 하나의 치료, 개선 및/또는 예방을 위한 의약 및/또는 식품 용도를 제공한다.The present invention provides a medicament and / or food use for the treatment, amelioration and / or prevention of either forgetfulness or degenerative brain disease of pogongyoung extract.
또한, 본 발명은 포공영 추출물을 유효성분으로 포함하는 건망증 또는 퇴행성 뇌질환 중 어느 하나의 치료 또는 예방용 약학 조성물을 제공한다.In another aspect, the present invention provides a pharmaceutical composition for the treatment or prevention of any forgetfulness or degenerative brain disease comprising a pogongyoung extract as an active ingredient.
상기 포공영 추출물은 물, 탄소수 1 내지 4의 저급 알콜, 및 이들의 혼합물 중에서 선택된 하나 이상의 용매에 가용한 추출물일 수 있으며, 바람직하게는 상기 포공영 추출물은 물 또는 물 및 에탄올 혼합용매에 가용한 추출물일 수 있으며, 보다 바람직하게는 물 또는 5 내지 80% 에탄올, 보다 더 바람직하게는 40 내지 80% 에탄올에 가용한 추출물일 수 있다.The pogongyoung extract may be an extract available in at least one solvent selected from water, a lower alcohol having 1 to 4 carbon atoms, and mixtures thereof, and preferably, the poongong extract is an extract available in water or a mixed solvent of water and ethanol. It may be more preferably water or extracts soluble in 5 to 80% ethanol, even more preferably 40 to 80% ethanol.
상기 퇴행성 뇌질환은 이로써 제한되는 것은 아니나, 예를 들어 뇌졸중, 중풍, 치매, 알츠하이머 질환, 파킨슨 질환, 및 헌팅턴 질환 중에서 선택된 하나 이상일 수 있으며, 바람직하게는 혈관성 치매 또는 알츠하이머 치매일 수 있다.The degenerative brain disease is not limited thereto, but may be, for example, one or more selected from stroke, stroke, dementia, Alzheimer's disease, Parkinson's disease, and Huntington's disease, and preferably may be vascular dementia or Alzheimer's dementia.
상기 퇴행성 뇌질환은 기억인지력 장애를 수반하는 것일 수 있다.The degenerative brain disease may be accompanied by memory cognitive impairment.
상기 조성물은 조성물 총 중량에 대하여 유효성분을 0.1 내지 50중량% 포함할 수 있으나, 반드시 이에 한정되는 것은 아니고 사용자의 상태 및 질환의 종류 및 진행정도에 따라 변화할 수 있다.The composition may include 0.1 to 50% by weight of the active ingredient based on the total weight of the composition, but is not necessarily limited thereto, and may vary depending on the type and progression of the condition and disease of the user.
상기 조성물은 유효성분 외에 약학적 조성물에 통상적으로 사용하는 적절한 담체, 부형제 및/또는 희석제를 더 포함할 수 있다.The composition may further include appropriate carriers, excipients and / or diluents commonly used in pharmaceutical compositions in addition to the active ingredient.
상기 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 이에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 마그네슘 스테아레이트 및/또는 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 제제화될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 제제화될 수 있다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, or the like, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Carriers, excipients and diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and / or mineral oil. When formulated, it may be formulated with diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose, or the like. Or lactose, gelatin and the like can be formulated. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
상기 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 유효성분 기준으로 1일 0.01 mg/kg 내지 10 g/kg으로, 바람직하게는 1 mg/kg 내지 1 g/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 그러므로 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the composition varies depending on the condition and the weight of the patient, the degree of the disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. However, for the desired effect, it is preferable to administer at 0.01 mg / kg to 10 g / kg, preferably 1 mg / kg to 1 g / kg per day based on the active ingredient. The administration may be carried out once a day or divided into several doses. Therefore, the dose is not intended to limit the scope of the present invention in any aspect.
상기 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구 및 직장, 또는 정맥주사 등의 방법을 통하여 투여할 수 있다.The composition can be administered to mammals such as mice, mice, livestock, humans, and the like by various routes. All modes of administration can be expected, for example by oral and rectal or intravenous methods.
또한, 본 발명은 포공영 추출물을 유효성분으로 포함하는 건망증 또는 퇴행성 뇌질환 중 어느 하나의 개선 또는 예방용 식품 조성물을 제공한다.In another aspect, the present invention provides a food composition for improving or preventing any of forgetfulness or degenerative brain disease comprising a pogongyoung extract as an active ingredient.
상기 식품은 캔디, 음료, 껌, 또는 차 등의 형태일 수 있다.The food may be in the form of candy, beverage, gum, tea, or the like.
또한, 상기 식품조성물은 건강기능식품, 또는 식품 첨가제일 수 있다.In addition, the food composition may be a health functional food, or a food additive.
상기 건강기능식품은 분말, 과립, 정제, 캡슐 또는 음료의 형태일 수 있다.The health functional food may be in the form of powder, granules, tablets, capsules or beverages.
별도의 언급이 없는 한 상기 식품 조성물은 본 발명의 약학조성물에서 언급된 사항이 모순되지 않는 한 동일하게 적용된다. 상기 '개선'은 '치료'에 포함되며, 상태 또는 증세가 호전되는 것을 의미한다.Unless otherwise stated, the food composition is equally applicable unless the contradictions mentioned in the pharmaceutical composition of the present invention are contradictory. The term 'improvement' is included in the 'treatment' and means that the condition or symptom is improved.
상기 식품조성물은 음료를 포함하는 식품에 다양하게 포함될 수 있다. 상기 건강기능식품이라 함은 대한민국 건강기능식품에 관한 법률 제10219호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조(가공을 포함한다. 이하 같다)한 식품을 말하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻는 것을 말한다. 상기 식품 조성물은 통상의 식품 첨가물을 포함할 수 있으며, 상기 식품 첨가물은 케톤류, 글리신, 구연산나트륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다.The food composition may be included in a variety of foods, including beverages. The health functional food refers to a food manufactured using a raw material or ingredient having functional functionality useful for the human body according to the Korean Health Functional Food Act No. 10219 (including processing. By means of nutrient control or physiological effects on the structure and function of the human body to obtain useful effects for health purposes. The food composition may include a conventional food additive, the food additive is a natural chemical such as ketones, glycine, sodium citrate, nicotinic acid, cinnamon acid, navy, licorice extract, crystalline cellulose, high pigment, guar gum And mixed preparations such as additives, sodium L-glutamate preparations, noodle addition alkalis, preservatives, and tar dyes.
포공영 추출물은 건망증 또는 퇴행성 뇌질환의 예방 및/또는 개선을 목적으로 식품(음료를 포함함)에 첨가될 수 있다. 이 때, 식품 중의 상기 추출물의 양은 일반적으로 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 음료 조성물은 100 ml를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. Pogongyoung extract may be added to food (including beverages) for the purpose of preventing and / or ameliorating forgetfulness or degenerative brain disease. At this time, the amount of the extract in the food may generally be added in 0.01 to 15% by weight of the total food weight, the beverage composition may be added in a ratio of 0.02 to 10 g, preferably 0.3 to 1 g based on 100 ml. have.
상기 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등)) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The beverage composition, in addition to containing the extract as an essential ingredient in the indicated ratio, there is no particular limitation on the liquid component and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
이하에서는 본 발명의 용도에 사용되거나, 조성물 중 포함되는 추출물을 수득하는 방법을 보다 상세하게 설명한다.Hereinafter, the method for obtaining the extract used in the use of the present invention or included in the composition will be described in more detail.
예를 들어, 포공영 추출물은 포공영을 세척 및 건조시킨 후, 시료 중량의 약 1배 내지 30배, 바람직하게는 약 5배 내지 15배 (v/w) 부피의 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합용매로, 바람직하게는 물 또는 물 및 에탄올 혼합용매, 보다 바람직하게는 물 또는 5 내지 80% 에탄올, 보다 더 바람직하게는 40 내지 80% 에탄올을 추출용매로 하여, 약 섭씨 30 내지 120도, 바람직하게는 40 내지 80도의 반응온도에서 약 30분 내지 6시간, 바람직하게는 1 시간 내지 3시간 동안 가열추출법, 초음파 추출법, 환류 추출법 등의 통상적인 추출방법, 바람직하게는 초음파추출법으로 1 내지 10회, 바람직하게는 2 내지 7회 반복 추출한 후, 추출액을 여과하여 감압 농축하고, 상기 농축된 추출물을 약 섭씨 -50 내지 -30도에서 약 24 내지 72시간 동결 건조하는 과정을 거쳐 수득할 수 있다.For example, the pogongyoung extract may be washed and dried, followed by about 1 to 30 times the weight of the sample, preferably about 5 to 15 times the volume of water (v / w), lower alcohol having 1 to 4 carbon atoms. Or a mixed solvent thereof, preferably water or water and an ethanol mixed solvent, more preferably water or 5 to 80% ethanol, even more preferably 40 to 80% ethanol as the extraction solvent, about 30 to Celsius Conventional extraction methods such as heat extraction, ultrasonic extraction and reflux extraction, preferably ultrasonic extraction, for about 30 minutes to 6 hours, preferably 1 hour to 3 hours at a reaction temperature of 120 degrees, preferably 40 to 80 degrees. After repeated
이외에, 상기 포공영 추출물은 약학적으로 또는 식품학적으로 허용되는 담체, 부형제 또는 희석제 등을 첨가하여 제제화할 수 있으며, 제제화에 관한 내용은 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA, 또는 식품공전 등의 문헌을 참조할 수 있다.In addition, the pogongyoung extract may be formulated by adding a pharmaceutically or food-acceptable carrier, excipient or diluent, etc. For formulation information, Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA, or See, eg, Food Code.
본 발명에 의해 건망증 또는 퇴행성 뇌질환 중 어느 하나를 효과적으로 치료, 개선 및/또는 예방할 수 있다.The present invention can effectively treat, ameliorate and / or prevent either forgetfulness or degenerative brain disease.
도 1은 포공영 추출물의 기억개선 효과를 수동회피실험에서 확인한 결과를 나타낸 그래프이다.
도 2 내지 도 3은 포공영 추출물의 기억개선 효과를 모리스 수중 미로실험에서 확인한 결과를 나타낸 그래프이다.
도 4 내지 도 5는 포공영 추출물의 기억개선 효과를 Y 미로 실험에서 확인한 결과를 나타낸 그래프이다.
도 6은 포공영 추출물이 아세틸콜린에스테라아제의 활성을 억제하여 기억력 및 인지능력 개선 효과가 있음을 확인한 그래프이다.1 is a graph showing the results of confirming the memory improvement effect of pogongyoung extract in manual avoidance experiment.
2 to 3 are graphs showing the results of the memory improvement effect of the pogongyoung extract confirmed in Morris water maze experiment.
4 to 5 are graphs showing the results of confirming the memory improvement effect of the pogongyoung extract in the Y maze experiment.
6 is a graph confirming that pogongyoung extract has an effect of improving the memory and cognitive ability by inhibiting the activity of acetylcholinesterase.
이하, 실시예 및 제조예에 의해 본 발명을 보다 상세하게 설명하나, 하기 실시예 및 제제예는 본 발명을 예시하기 위한 것일 뿐으로 본 발명의 내용이 하기 실시예나 제조예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples and Preparation Examples, but the following Examples and Formulation Examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
본 발명에 있어서, 포공영(蒲公英)은 민들레 Taraxacum platycarpum H. Dahlstedt, 서양민들레 Taraxacum offficinale Weber, 털민들레 Taraxacum mongolicum Handel-Mazzetti, 또는 흰민들레 Taraxacum coreanum Nakai(국화과 Compositae)의 전초를 포괄하는 의미이다(대한약전외 한약(생약) 규격집 참조).In the present invention, pogongyoung (의미 公 英) is meant to encompass the outposts of Dandelion Taraxacum platycarpum H. Dahlstedt, Taraxacum offficinale Weber, Taraxacum mongolicum Handel-Mazzetti, or Taraxacum coreanum Nakai (Chrysanthemum Compositae). See the Pharmacopoeia Herbal Medicine Specification).
건망증 내지 뇌졸중, 중풍, 치매, 알츠하이머 질환, 파킨슨 질환, 또는 헌팅턴 질환과 같이 특히 기억인지력 장애를 수반하는 퇴행성 뇌질환의 특징을 나타내는 기억력 감퇴 모델(스코폴라민 처리 모델)을 이용하여, 포공영 추출물이 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방 효과를 가짐을 아래와 같은 방법으로 확인하였다.Using a memory decay model (scopolamine treatment model) that characterizes degenerative brain disorders, especially those with memory cognitive impairment, such as forgetfulness to stroke, stroke, dementia, Alzheimer's disease, Parkinson's disease, or Huntington's disease, It was confirmed by the following method to have a treatment, improvement and / or prevention effect of forgetfulness to degenerative brain disease.
하기 실시예 중 스코폴라민(scopolamin; S1875), 타크린 (tacrine; A3773)은 Sigma-Aldrich Chemistry Co. 에서 구입하여 사용하였으며, 그 외 시약은 시중에서 구입할 수 있는 최상급을 사용하였다. 포공영는 계림약업사(대구, 대한민국)에서 구입하여 사용하였다.In the following examples, scopolamine (scopolamin; S1875) and tacrine (tacrine; A3773) are described in Sigma-Aldrich Chemistry Co. The reagents were purchased from and used, and the best reagents commercially available were used. Pogongyoung was purchased from Guilin Pharmaceutical Co., Ltd. (Daegu, Korea).
또한, 실험동물은 6주령의 ICR 마우스 (26 - 28g)를 대한바이오링크(충북, 대한민국)에서 공급받아 대구한의대학교 한방산업대학의 소독케이지(clean cage)에 약 5일간 적응시켜 사용하였으며, 물과 사료는 자유롭게 섭취하도록 하였고, 온도(섭씨 23±2도), 습도 (55±10%) 및 명암주기 (12 시간)는 자동으로 조절되도록 하였다.In addition, the experimental animals were supplied with 6-week-old ICR mice (26-28g) from Daehan Biolink (Chungbuk, Korea) and used for 5 days in a clean cage at Daegu Haany University College of Oriental Medicine. Water and feed were allowed freely, and the temperature (23 ± 2 degrees Celsius), humidity (55 ± 10%) and contrast cycle (12 hours) were automatically controlled.
한편, 모든 실험결과는 one-way ANOVA (one way analysis of variance)를 이용하여 통계 처리하였고, 유의성이 인정될 경우 Student-Newman-Keuls Test를 사용하여 p < 0.05 수준 이하에서 유의성 검정을 실시하였다.
On the other hand, all experimental results were statistically processed using one-way ANOVA (one way analysis of variance), and the significance test was conducted at p <0.05 level using Student-Newman-Keuls Test when significance was recognized.
<실시예 1> 수동회피실험에서, 포공영 추출물의 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방 효과 확인<Example 1> In the passive avoidance experiment, confirmed the treatment, improvement and / or preventive effect of forgetfulness to degenerative brain disease of pogongyoung extract
포공영 추출물(WTP)의 수동회피실험에서의 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방 효과를 확인하기 위하여 문헌에 개시된 방법을 응용하여 하기와 같이 실험을 수행하였다(Kim DH, Jeon SJ, Son KH, Jung JW, Lee S, Yoon BH, Lee JJ, Cho YW, Cheong JH, Ko KH, Ryu JH. The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice, Neurobiol Learn Mem, 87, pp.536-546, 2007 참조).
In order to confirm the treatment, improvement and / or prophylactic effect of forgetfulness to degenerative brain disease in passive evacuation experiment of pogongyoung extract (WTP), the experiments were carried out as follows (Kim DH, Jeon SJ, Son KH, Jung JW, Lee S, Yoon BH, Lee JJ, Cho YW, Cheong JH, Ko KH, Ryu JH.The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice, Neurobiol Learn Mem, 87, pp. 536-546, 2007).
1-1. 포공영 추출물 준비1-1. Pogongyoung extract preparation
계림약업사(대구, 대한민국)에서 건조된 포공영 100 g을 구입하여 완전히 건조시킨 후에 분쇄하여 10배(v/w)의 증류수를 가하여 환류 냉각장치(pyrex, CD1100-300)에서 섭씨 80~100도로 2시간 추출하였으며, 추출완료 후, 추출액을 Whatman (No. 1) 여과지(filter paper)로 여과하고, 여액을 일정 부피가 될 때까지 감압농축 및 동결건조 (Eyela, model FDU-2000, Japan)하여 포공영 물 추출물(이하, WTP라 명명함.) 22.3 g을 수득하였다(수득율 : 22.3%).
Buy 100 g of dried pogongyoung from Guilin Pharmaceutical Co., Ltd. (Daegu, Korea), dry it completely, grind it, add 10 times (v / w) of distilled water, and use 80 ~ 100 degrees Celsius in reflux cooling system (pyrex, CD1100-300). After extraction, extraction was completed, the extract was filtered with Whatman (No. 1) filter paper, and the filtrate was concentrated under reduced pressure and lyophilized (Eyela, model FDU-2000, Japan) until it became a certain volume. 22.3 g of a water extract (hereinafter referred to as WTP) were obtained (yield: 22.3%).
1-2. 수동회피실험1-2. Manual Evasion Experiment
상기 1-1.에서 준비된 포공영 추출물(WTP)을 10% 트윈 80(Polyoxyethyl enesorbitan monooleate : Sigma, U.S.A.)에 녹인 후 여러 가지 용량(0, 6.25, 12.5, 25, 50 mg/kg)으로 준비된 실험동물에 경구로 투여하였다. 양성 대조군은 tacrine 10 mg/kg을 투여하고, 대조군(control)에는 10% 트윈을 투여하였다.Experimental animals prepared at various doses (0, 6.25, 12.5, 25, 50 mg / kg) after dissolving pogongyoung extract (WTP) prepared in 1-1 in 10% Tween 80 (Polyoxyethyl enesorbitan monooleate: Sigma, USA) Administered orally. Positive control group was administered
이 후, 본 실험(Test trial) 이전에 학습시험(Training trial)을 하기 방법으로 실시하였다.Thereafter, the training trial was conducted before the test trial in the following manner.
약물투여 30분 후에 증류수에 녹인 스코폴라민을 1 mg/kg의 용량으로 복강 투여하고, 스코폴라민 투여 30분 후에 실험동물을 조명을 비춘 밝은 쪽 구획에 놓고 20초의 탐색시간 후 길로틴문 (guillotine door)이 열려 어두운 구획으로 들어갈 수 있게 하였다. 이때 길로틴문이 열린 후 40초 이내에 어두운 쪽으로 들어가지 않는 쥐는 실험에서 제외시켰다. 길로틴문이 열린 후 쥐가 어두운 쪽으로 들어갈 때까지의 시간을 측정하였다. 일단 쥐가 어두운쪽으로 들어가면 길로틴문이 닫히고 0.5mA의 전기 충격이 3초 동안 격자 바닥을 통해 흐르게 되고 쥐는 이러한 전기충격을 기억하게 된다.30 minutes after drug administration, scopolamine dissolved in distilled water was intraperitoneally administered at a dose of 1 mg / kg, and 30 minutes after scopolamine administration, the animals were placed in a brightly lit compartment with a guilotine after 20 seconds of search time. The door was opened to allow access to the dark compartment. Mice that did not enter the dark side within 40 seconds after the guillotine door was opened were excluded from the experiment. After the guillotine door was opened, the time until the rat entered the dark side was measured. Once the rat enters the dark side, the guillotine door closes and a 0.5 mA electric shock flows through the bottom of the grid for three seconds, and the mouse remembers this electric shock.
이와 같은 학습 시험이 끝나고, 24시간 후에 본 실험(Test trial)을 실시하였다. 쥐가 20초의 탐색시간 후 길로틴문이 열리고 어두운 쪽으로 4발이 다 들어가는데 걸리는 시간(latency time : 머무름 시간)을 180초까지 측정하였다. 걸리는 시간이 길수록 수동회피의 학습과 기억이 좋음을 나타낸다.After this learning test, a test trial was conducted 24 hours later. After 20 seconds of searching time, the time required for the guillotine door to open and four shots to the dark side (latency time) was measured up to 180 seconds. The longer the time taken, the better the learning and memory of passive avoidance.
그 결과를 도 1에 나타내었다.The results are shown in Fig.
도 1은 수동회피실험에서 스코폴라민으로 유도된 기억력 감퇴 모델에서 포공영 추출물(WTP)의 용량(6.25, 12.5, 25, 및 50 mg/kg)에 따른 개선효과를 나타낸 그래프이다. 도 1에서 각 그룹은 10마리의 생쥐를 사용하였고, 머무름시간(Latency time)은 평균±표준편차로 나타내었다.1 is a graph showing the improvement effect according to the dose (6.25, 12.5, 25, and 50 mg / kg) of pogongyoung extract (WTP) in the scopolamine-induced memory loss model in a passive avoidance experiment. In FIG. 1, 10 mice were used in each group, and the retention time was expressed as the mean ± standard deviation.
도에서 보는 바와 같이, 모든 실험군이 대조군에 비해 스코폴라민만 투여한 경우 머무름 시간이 유의성 있게 감소한 것으로 보아 기억력 감퇴 모델이 제작되었음을 알 수 있었다. 또한, 포공영 추출물(WTP)의 용량의존성 실험에서는 도 1에서 보듯이 스코폴라민만 투여한 그룹의 머무름 시간이 31.1±5.0초인데 반해 25, 50 mg/kg 투여군에서 각각 119±29.6(p < 0.05), 129±15.1 (p < 0.05)초로 유의성 있는 증가를 보였다. As shown in the figure, the retention time was significantly reduced when all the experimental groups were administered scopolamine compared to the control group, it can be seen that the memory loss model was produced. In addition, in the dose-dependent experiment of pogongyoung extract (WTP), as shown in Fig. 1, the retention time of the scopolamine-only group was 31.1 ± 5.0 seconds, whereas 119 ± 29.6 ( p <0.05) in the 25 and 50 mg / kg administration groups, respectively. ), 129 ± 15.1 ( p <0.05) seconds.
이와 같은 결과로부터 포공영 추출물은 기억력 감퇴에 용량 의존적으로 효과를 나타냄을 알 수 있다. 따라서, 기억력 감퇴와 관련된 건망증 내지 뇌졸중, 중풍, 치매, 알츠하이머 질환, 파킨슨 질환, 또는 헌팅턴 질환과 같이 특히 기억인지력 장애를 수반하는 퇴행성 뇌질환의 치료, 개선 등이 가능할 뿐만 아니라, 증세가 악화되는 것을 막는 예방 효과도 갖는 것으로 보인다.These results indicate that pogongyoung extract has a dose-dependent effect on memory loss. Thus, not only is it possible to treat or improve degenerative brain diseases involving memory cognitive impairment, such as forgetfulness to stroke, stroke, stroke, dementia, Alzheimer's disease, Parkinson's disease, or Huntington's disease associated with memory loss, but also worsen the symptoms The membrane also appears to have a prophylactic effect.
결과적으로, 포공영 추출물은 건망증 및/또는 퇴행성 뇌질환을 효과적으로 치료, 개선 또는 예방할 수 있음을 알 수 있다.
As a result, it can be seen that pogongyoung extract can effectively treat, ameliorate or prevent forgetfulness and / or degenerative brain disease.
<실시예 2> Morris 수중미로장치 실험에서, 포공영 추출물의 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방 효과 확인Example 2 In Morris Morris Maze Experiment, Confirmation of Treatment, Improvement and / or Prevention of Forgetfulness to Degenerative Brain Disease of Pogongyoung Extract
포공영 추출물(WTP)의 Morris 수중미로 실험에서 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방 효과를 확인하기 위하여 문헌에 개시된 방법을 응용하여 하기와 같이 실험을 수행하였다(Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. pp.47-60. 1984 참조).
In order to confirm the treatment, improvement and / or prophylactic effect of forgetfulness to degenerative brain disease in Morris water maze experiment of pogongyoung extract (WTP), experiments were performed as follows (Morris R. Developments of a water-maze procedure for studying spatial learning in the rat.J. Neurosci.Methods.pp. 47-60.1984).
2-1. 포공영 추출물 준비2-1. Pogongyoung extract preparation
실시예 1의 1-1.과 동일한 방법으로 포공영 추출물을 준비하였다.
A pogongyoung extract was prepared in the same manner as in Example 1-1.
2-2. Morris 수중미로장치 실험2-2. Morris Underwater Maze Experiment
상기 2-1에서 준비한 포공영 추출물(WTP)을 10% 트윈 80(Polyoxyethyl enesorbitan monooleate : Sigma, U.S.A.)에 녹인 후 여러 가지 용량(0, 6.25, 12.5, 25, 50mg/kg)으로 실험동물에 경구로 투여하였다. 양성 대조군은 tacrine 10 mg/kg을 투여하고, 대조군(control)에는 10% 트윈 80을 투여하였다. 포공영 추출물 투여군과 양성 대조군 각각에 대하여는 약물투여 30분 후에 증류수에 녹인 스코폴라민을 1 mg/kg의 용량으로 4일 동안 복강 투여하여 기억력 손상을 유발하였으며, 매일 4 번씩 4일 동안 Morris 수중미로 검사 (Morris water-maze test)를 실시하였다. 수중미로 장치는 지름 90 cm, 높이 45 cm이며 플랫폼 (white platform)의 지름은 6 cm로 구성되어 있다. 수중미로의 주변은 비디오카메라와 연결된 컴퓨터 시스템(Ethovision, Noldus, 네델란드)과 수온 조절용 장치 등 공간단서들을 항상 일정하게 유지시켰다, 실험방법으로는 maze에 물의 높이가 30 cm가 되도록 물을 채우고 마우스가 플랫폼을 볼 수 없도록 플랫폼을 물 높이의 1 cm 밑에 설치하였다. 마우스가 플랫폼까지 찾아가서 플랫폼에서 10초 이상 머무르면 찾아갈 때까지 걸린 시간을 탈출잠복기(escape latency)로 하였으며, 이를 하루 4회 실시하여 나온 평균값을 데이터로 사용하였다. 이때 평균탈출 잠복기가 60 초를 초과하는 경우에는 60초로 동일한 값을 취하였다. 마지막 5일째 날에는 플랫폼을 maze에서 제거한 후 플랫폼이 있던 위치에 마우스가 머문 시간을 측정하였다. 각 그룹은 10마리의 생쥐를 사용하였다.The pogongyoung extract (WTP) prepared in 2-1 above was dissolved in 10% Tween 80 (Polyoxyethyl enesorbitan monooleate: Sigma, USA) and then orally in experimental animals at various doses (0, 6.25, 12.5, 25, 50 mg / kg). Administered. Positive control group was administered
도 2와 도 3에 그 결과를 나타내었다.2 and 3 show the results.
도 2 내지 도 3은 Morris 수중미로 실험에서 스코폴라민으로 유도된 기억력 감퇴 모델에서 포공영 추출물(WTP)의 6.25, 12.5, 25, 50 mg/kg의 기억력 개선효과를 나타낸 것으로, 도 2는 4일간의 잠복기 시간(Latency time) 변화를 나타낸 그래프이고, 도 3은 5일 째 플랫폼이 있던 위치에 마우스가 머문 시간(Swimming time in target quadrant)을 나타낸 그래프이다.2 to 3 show the improvement of memory of 6.25, 12.5, 25, 50 mg / kg of pogongyoung extract (WTP) in the scopolamine-induced memory decay model in Morris underwater maze experiment, Figure 2 is 4 days Figure 3 is a graph showing the change in latency time (Latency time), Figure 3 is a graph showing the time (Swimming time in target quadrant) the mouse stayed in the position where the platform was on the 5th day.
도 2에서 보는 바와 같이, Morris 수중미로 학습에서 4일 동안 60초 이내 플랫폼에 도달하기까지의 소요시간을 측정하는 학습시험에서 학습이 진행됨에 따라 대조군(control)은 플랫폼을 찾아가는 시간이 13.1±2.6초로 현저히 감소하였으며, 스코폴라민 투여군(Scopolamine)은 55.2±1.8초로 거의 플랫폼을 찾아가지 못한 반면, 포공영 추출물(WTP) 투여군은 25, 50 mg/kg의 용량이 각 각 20.8±2.2, 15±1.2초로 플랫폼을 찾아가는 시간이 감소함을 확인하였다(p < 0.05).As shown in Figure 2, as learning progress in the learning test to measure the time required to reach the platform within 60 seconds for 4 days in Morris underwater maze learning, the control (control) is 13.1 ± 2.6 The scopolamine treated group (Scopolamine) rarely found a platform (55.2 ± 1.8 seconds), whereas the OWG-treated group had doses of 25, 50 mg / kg, 20.8 ± 2.2 and 15 ± 1.2, respectively. The time to visit the platform was found to be reduced by seconds ( p <0.05).
또한, 도 3에서 보는 바와 같이, Morris 수중미로 학습에서 마지막 날인 제 5일째 기억검사에서도 포공영 추출물(WTP) 25, 50 mg/kg 투여군에서 scopolamine 손상군(WTP 0 mg/kg, scopolamine 1mg/kg 투여군)에 비해 유의성 있는 증가를 보였다(p < 0.05).In addition, as shown in Figure 3, the scopolamine damaged group (
이와 같은 결과로부터 포공영 추출물은 기억력 감퇴에 효과를 나타냄을 알 수 있다. 따라서, 기억력 감퇴와 관련된 건망증 내지 뇌졸중, 중풍, 치매, 알츠하이머 질환, 파킨슨 질환, 또는 헌팅턴 질환과 같이 특히 기억인지력 장애를 수반하는 퇴행성 뇌질환의 치료, 개선 등이 가능할 뿐만 아니라, 증세가 악화되는 것을 막는 예방 효과도 갖는 것으로 보인다.From these results, it can be seen that pogongyoung extract has an effect on memory loss. Thus, not only is it possible to treat or improve degenerative brain diseases involving memory cognitive impairment, such as forgetfulness to stroke, stroke, stroke, dementia, Alzheimer's disease, Parkinson's disease, or Huntington's disease associated with memory loss, but also worsen the symptoms The membrane also appears to have a prophylactic effect.
결과적으로, 포공영 추출물은 건망증 및/또는 퇴행성 뇌질환을 효과적으로 치료, 개선 또는 예방할 수 있음을 알 수 있다.
As a result, it can be seen that pogongyoung extract can effectively treat, ameliorate or prevent forgetfulness and / or degenerative brain disease.
<실시예 3> Y 미로 시험(Y-maze test)에서, 포공영 추출물의 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방 효과 확인Example 3 Confirmation of the Treatment, Improvement and / or Prevention Effect of Forgetfulness to Degenerative Brain Disease in the Y-maze Test
포공영 추출물(WTP)의 Y 미로시험에서의 포공영 추출물의 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방을 효과 확인하기 위하여 문헌에 개시된 방법을 응용하여 하기와 같이 실험을 수행하였다(Sarter M, Bodewitz G, Stephens DN. Attenuation of scopolamineinduced impairment of spontaneous alternation behavior by antagonist but not inverse agonist and betacarboline. Psycopharmacology. pp.491-495. 1998 참조).
In order to confirm the effect of treating, ameliorating and / or preventing the forgetfulness to degenerative brain disease of the pogongyoung extract in the Y maze test of the pogongyoung extract (WTP), the experiments were conducted as described below (Sarter M, Bodewitz G, Stephens DN.Attenuation of scopolamineinduced impairment of spontaneous alternation behavior by antagonist but not inverse agonist and betacarboline.Psycopharmacology.pp. 491-495. 1998).
3-1. 포공영 추출물 준비3-1. Pogongyoung extract preparation
실시예 1의 1-1.과 동일한 방법으로 포공영 추출물을 준비하였다.
A pogongyoung extract was prepared in the same manner as in Example 1-1.
3-2. Y 미로 시험3-2. Y maze test
3-1.에서 준비한 포공영 추출물(WTP)을 10% 트윈 80(Polyoxyethyl enesorbitan monooleate : Sigma, U.S.A.)에 녹인 후 여러 가지 용량(0, 6.25, 12.5, 25, 50 mg/kg)으로 경구로 투여하였다. 양성 대조군은 tacrine 10 mg/kg을 투여하고 대조군(control)에는 10% 트윈 80을 투여하였다. 포공영 추출물 투여군과 양성대조군 각각에 대하여는 약물투여 30분 후에 증류수에 녹인 스코폴라민을 1 mg/kg의 용량으로 복강 투여하여 기억력 손상을 유발한 후, Y-미로시험(Y-maze test)을 실시하였다.The pogongyoung extract (WTP) prepared in 3-1. Was dissolved in 10% Tween 80 (Polyoxyethyl enesorbitan monooleate: Sigma, USA) and administered orally at various doses (0, 6.25, 12.5, 25, 50 mg / kg). . A positive control group was administered
Y-미로시험에 이용되는 기구는 3개의 가지로 구성되어 있으며 각 가지(arm)의 길이는 42 cm, 넓이는 3 cm, 높이는 12 cm이고 세 가지가 접하는 각도는 120도이다. 모든 실험 장치는 검정색의 폴리비닐 플라스틱(polyvinyl plastic)으로 구성되어 있다. 각 가지를 A, B, C로 정한 후 한쪽 가지에 마우스를 조심스럽게 놓고 8분 동안 자유롭게 움직이게 한 다음 마우스가 들어간 가지를 기록하였다. 이 때 꼬리까지 완전히 들어갔을 경우에 한하며, 갔던 가지에 다시 들어간 경우에도 기록하였다. 세 개의 서로 다른 가지에 차례로 들어간 경우 1점(실제 변경, actual alternation)씩 부여하였다. 변경 행동력(alternation behavior 또는 Spontaneous alternation)은 3가지 모두에 차례로 들어가는 것으로 정의되며, 하기 수학식 1에 의해 계산된다. 각 그룹은 10마리의 생쥐를 사용하였다.
The instrument used for the Y-maze test consists of three branches, each arm is 42 cm long, 3 cm wide, 12 cm high and the angle of contact between the three is 120 degrees. All experimental devices consisted of black polyvinyl plastic. Each branch was set to A, B, and C, and the mouse was carefully placed on one branch, and allowed to move freely for 8 minutes, and then the branch containing the mouse was recorded. Only when the tail is completely entered, it is also recorded when the branch went back. One point (actual alteration) was given to three different branches in turn. Alteration behavior (spontaneous alternation) is defined as entering all three in turn, and is calculated by
수학식Equation 1 One
변경행동력(%) = 실제변경(actual alternation)/최고변경(maximum alterantion)×100 (최고변경:총입장횟수-2)% Of change behavior = actual alteration / maximum alterantion × 100 (maximum change: total number of entrances-2)
도 4와 도 5에 그 결과를 나타내었다.4 and 5 show the results.
도 4 내지 도 5는 Y 미로 실험에서 스코폴라민으로 유도된 기억력 감퇴 모델에서 포공영의 70% 에탄올 추출물(WTP)의 용량(6.25, 12.5, 25, 및 50 mg/kg)에 따른 개선효과를 나타낸 것으로, 도 4는 총입장횟수(Total entry)를 투여군별로 나타낸 결과 그래프이고, 도 5는 변경행동력을 나타내는 자발적 교차행동(spontaneous alternation) 비율을 투여군별로 나타낸 결과 그래프이다.4 to 5 show the improvement effect according to the dose (6.25, 12.5, 25, and 50 mg / kg) of pogongyoung 70% ethanol extract (WTP) in the scopolamine-induced memory loss model in the Y maze experiment 4 is a result graph showing the total entry number by administration group, and FIG. 5 is a result graph showing the spontaneous alternation ratio indicating the alteration behavior by administration group.
그 결과, 스코폴라민 (1 mg/kg, i.p.)의 투여에 의해 spontaneous alternation이 대조군에 비해 통계적으로 유의성 있게 감소하고, 포공영 추출물(WTP) 25 및 50 mg/kg의 투여에 의해 spontaneous alternation이 scopolamine 투여군(0mg/kg WTP+Scopolamine 1mg/kg 투여군)에 비해 증가하여 학습 및 기억력이 회복되었다는 것을 확인하였다(p < 0.05).As a result, spontaneous alternation was statistically significantly reduced by the administration of scopolamine (1 mg / kg, ip) compared to the control group, and spontaneous alternation was reduced by the administration of 25 and 50 mg / kg polipoglutin extract (WTP). Compared with the administration group (0 mg / kg WTP +
이와 같은 결과로부터 포공영 추출물은 기억력 감퇴에 효과를 나타냄을 알 수 있다. 따라서, 기억력 감퇴와 관련된 건망증 내지 뇌졸중, 중풍, 치매, 알츠하이머 질환, 파킨슨 질환, 또는 헌팅턴 질환과 같이 특히 기억인지력 장애를 수반하는 퇴행성 뇌질환의 치료, 개선 등이 가능할 뿐만 아니라, 증세가 악화되는 것을 막는 예방 효과도 갖는 것으로 보인다.From these results, it can be seen that pogongyoung extract has an effect on memory loss. Thus, not only is it possible to treat or improve degenerative brain diseases involving memory cognitive impairment, such as forgetfulness to stroke, stroke, stroke, dementia, Alzheimer's disease, Parkinson's disease, or Huntington's disease associated with memory loss, but also worsen the symptoms The membrane also appears to have a prophylactic effect.
결과적으로, 포공영 추출물은 건망증 또는 퇴행성 뇌질환을 효과적으로 치료, 개선 및/또는 예방할 수 있음을 알 수 있다.
As a result, it can be seen that pogongyoung extract can effectively treat, ameliorate and / or prevent forgetfulness or degenerative brain disease.
<실시예 4> 포공영 추출물의 아세틸콜린에스테라아제 활성 억제에 의한 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방 효과 확인Example 4 Confirmation of Treatment, Improvement and / or Preventive Effect of Forgetfulness to Degenerative Brain Disease by Inhibiting Acetylcholinesterase Activity of Pogongyoung Extract
포공영 추출물(WTP)의 아세틸콜린에스테라아제 활성 억제에 의한 건망증 내지 퇴행성 뇌질환의 치료, 개선 및/또는 예방을 효과 확인하기 위하여 문헌에 개시된 방법을 응용하여 하기와 같이 실험을 수행하였다(Ellman GL, courtney KD, Andres JrV and Feather-Stone RM. A new and rapid colormetric determination of acetylcholinesterase activity. Biochem Pharmacol. 7;88-95. 1961 참조).
In order to confirm the effect of treatment, improvement and / or prevention of forgetfulness to degenerative brain disease by inhibiting the acetylcholinesterase activity of the pogongyoung extract (WTP), experiments were conducted as follows (Ellman GL, courtney KD, Andres Jr V and Feather-Stone RM.A new and rapid colormetric determination of acetylcholinesterase activity.Biochem Pharmacol. 7; 88-95.1961).
4-1. 포공영 추출물 준비4-1. Pogongyoung extract preparation
실시예 1의 1-1.과 동일한 방법으로 포공영 추출물을 준비하였다.
A pogongyoung extract was prepared in the same manner as in Example 1-1.
4-2. 뇌 조직 아세틸콜린에스테라제(AchE) 활성 측정4-2. Brain tissue acetylcholinesterase (AchE) activity measurement
(1) 시약(1) Reagent
아세틸콜린에스테라아제(acetylcholinesterase)의 활성을 측정하는 데 사용한 아세틸콜린에스테라아제, 아세틸치오콜린 요오드화물 (acetylthiocholine iodide), 5,5-디티오-비스-(2-니트로벤조산), 네오스티그민 브로미드(neostigmine bromide)는 Sigma-Aldrich Chemistry Co.에서 구입하여 사용하였다.Acetylcholinesterase, acetylthiocholine iodide, 5,5-dithio-bis- (2-nitrobenzoic acid), neostigmine bromide used to measure the activity of acetylcholinesterase bromide) was purchased from Sigma-Aldrich Chemistry Co. and used.
(2) 실험 방법(2) Experimental method
4-1.에서 준비한 포공영 추출물(WTP)과 양성 대조군인 tacrine을 PBS에 녹여, 각각 0.01, 0.1, 10, 100, 1000 ug/ml의 용량이 되도록 하여 각 시료를 준비하였다.The pogongyoung extract (WTP) prepared in 4-1. And tacrine, a positive control, were dissolved in PBS, and each sample was prepared to have a dose of 0.01, 0.1, 10, 100, 1000 ug / ml, respectively.
아세틸콜린에스테라아제 저해 활성 측정은 Ellman법에 따라 행하였다 (Ellman et al., 1961). 마우스의 뇌를 적출하여 10배 부피의 인산완충용액(12.5 mM sodium phosphate buffer pH 7.0, 400mM NaCl)에 넣고 테플론 글래스 튜브를 이용하여 뇌 조직을 갈아서 1000 xg에서 10분간 4℃에서 원심분리 한 후 그 상등액을 효소로 사용하였다. 앞서 준비한 약물 10 ㎕와 인산완충용액(12.5 mM sodium phosphate buffer pH 7.0, 400mM NaCl) 640 ㎕, Ellman's 시약 (buffered Ellman's reagent: 10 mM DTNB(5.5'-dithiobis-bis(2-nitrobenzoic acid)) 25 ㎕, 효소용액 100 ㎕를 모두 섞어서 실온에서 30분간 전배양한 후 75mM 아세틸치오콜린 요오드화물 5 ㎕를 첨가하여 실온에서 10분간 배양한다. 이후에 정지시약인 Neostigmine bromide (Sigma, U.S.A) 10 ㎕를 첨가한 후 410nm에서 흡광도(O.D.)를 측정하였다.Acetylcholinesterase inhibitory activity was measured according to the Ellman method (Ellman et al., 1961). The brains of the mice were extracted and placed in a 10-fold volume of phosphate buffer solution (12.5 mM sodium phosphate buffer pH 7.0, 400 mM NaCl), and the brain tissues were ground using a Teflon glass tube and centrifuged at 1000 xg for 10 minutes at 4 ° C. Supernatants were used as enzymes. 10 μl of the prepared drug and 640 μl of phosphate buffer solution (12.5 mM sodium phosphate buffer pH 7.0, 400 mM NaCl), 25 μl of Ellman's reagent (buffered Ellman's reagent: 10 mM DTNB (5.5'-dithiobis-bis (2-nitrobenzoic acid)) After mixing all 100 μl of enzyme solution, pre-incubate for 30 minutes at room temperature, add 5 μl of 75mM acetylthiocholine iodide and incubate for 10 minutes at room temperature, then add 10 μl of stop reagent Neostigmine bromide (Sigma, USA). After absorbance (OD) was measured at 410nm.
아세틸콜린에스테라아제 저해능은 다음의 식에 의해 계산되었다.Acetylcholinesterase inhibitory activity was calculated by the following equation.
도 6에 그 결과를 나타내었다. 6 shows the result.
도 6은 포공영 추출물(WTP)의 아세틸콜린에스테라아제(acetylcholinesterase) 활성 억제 실험결과를 나타낸 것으로, x축은 포공영 추출물 및 타크린의 농도(ug/ml)를 나타내고, y축은 AchE 활성억제율(%)을 나타낸다.Figure 6 shows the experimental results of the inhibition of acetylcholinesterase activity of the siphon extract (WTP), the x-axis shows the concentration (ug / ml) of the siege extract and tacrine, the y-axis shows the inhibition rate of AchE activity (%) .
그 결과, 양성대조군(tacrine)은 용량 의존적으로 아세틸콜린에스테라아제 활성을 억제하고, 포공영 추출물 역시 타크린과 같이 용량의존적으로 아세틸콜린에스테라아제 활성을 억제하였다. IC50 값은 1.119 ug/ml였다.As a result, the positive control (tacrine) inhibited acetylcholinesterase activity in a dose-dependent manner, and pogongyoung extract also inhibited acetylcholinesterase activity in a dose-dependent manner, like tacrine. IC 50 value was 1.119 ug / ml.
이와 같은 결과로부터 포공영 추출물은 타크린과 같이 아세틸콜린에스테라아제 활성을 억제하여 기억력 및 인지능력 개선 작용을 나타낸다고 볼 수 있다. 따라서, 기억력 감퇴와 관련된 건망증 내지 뇌졸중, 중풍, 치매, 알츠하이머 질환, 파킨슨 질환, 또는 헌팅턴 질환과 같이 특히 기억인지력 장애를 수반하는 퇴행성 뇌질환의 치료, 개선 등이 가능할 뿐만 아니라, 증세가 악화되는 것을 막는 예방 효과도 갖는 것으로 보인다.From these results, pogongyoung extract can be seen to exhibit the effect of improving the memory and cognitive ability by inhibiting the acetylcholinesterase activity like tacrine. Thus, not only is it possible to treat or improve degenerative brain diseases involving memory cognitive impairment, such as forgetfulness to stroke, stroke, stroke, dementia, Alzheimer's disease, Parkinson's disease, or Huntington's disease associated with memory loss, but also worsen the symptoms The membrane also appears to have a prophylactic effect.
결과적으로, 포공영 추출물은 건망증 또는 퇴행성 뇌질환을 효과적으로 치료, 개선 및/또는 예방할 수 있음을 알 수 있다.
As a result, it can be seen that pogongyoung extract can effectively treat, ameliorate and / or prevent forgetfulness or degenerative brain disease.
제제예Formulation example 1. One. 산제의Sanje 제조 Produce
WTP 200 mg
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above components are mixed and filled in airtight bags to prepare powders.
제제예Formulation example 2. 정제의 제조 2. Preparation of tablets
WTP 200 mg
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components and tableting according to the conventional tablet manufacturing method to prepare a tablet.
제제예Formulation example 3. 캅셀제의 제조 3. Preparation of capsules
WTP 200 mg
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium Stearate 0.2 mg
통상의 캅셀제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캅셀제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of injections
WTP 200 mg
만니톨 180 mgMannitol 180 mg
주사용 멸균 증류수 2974 mgSterile distilled water for injection 2974 mg
Na2HPO4,12H2O 26 mgNa 2 HPO 4 , 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2ml) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, it is prepared in the above-mentioned ingredient content per 2 ampoules.
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
WTP 200 mg
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to the conventional method of preparing a liquid solution, each component is added to the purified water to dissolve it, and lemon flavor is added thereto, then the above ingredients are mixed, adjusted to 100 ml by adding purified water, and then filled into a brown bottle and sterilized to prepare a liquid solution. do.
제제예Formulation example 6. 건강기능식품의 제조 6. Manufacture of health functional foods
WTP 1000 mgWTP 1000 mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ugVitamin A
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 ugVitamin B12 0.2 ug
비타민 C 10 mg
비오틴 10 ug
니코틴산아미드 1.7 mgNicotinamide 1.7 mg
엽산 50 ug
판토텐산 칼슘 0.5 mgCalcium Pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture
황산제1철 1.75 mgFerrous Sulfate 1.75 mg
산화아연 0.82 mgZinc Oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mg15 mg potassium monophosphate
제2인산칼슘 55 mgDicalcium Phosphate 55 mg
구연산칼륨 90 mgPotassium Citrate 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients may be mixed according to a general health functional food manufacturing method. Next, the granules may be prepared and used for preparing the nutraceutical composition according to a conventional method.
제제예Formulation example 7. 건강기능식품(음료)의 제조 7. Preparation of health functional food (beverages)
WTP 1000 mgWTP 1000 mg
구연산 1000 mgCitric acid 1000 mg
올리고당 100 g100 g oligosaccharides
매실농축액 2 gPlum concentrate 2 g
타우린 1 g1 g of taurine
정제수를 가하여 전체 900 mlAdd 900 ml of purified water
통상의 건강기능식품(음료) 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 섭씨 85도에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2L용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 건강기능식품(음료) 조성물 제조에 사용한다. After mixing the above components in accordance with the conventional manufacturing method of health functional food (beverage), and then stirred and heated at 85 degrees Celsius for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2L container, sealed sterilization and refrigerated It is stored and then used to make health functional food (beverage) compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, use purpose.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120045772A KR101380568B1 (en) | 2012-04-30 | 2012-04-30 | Novel use of extract of Pogongyeong |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120045772A KR101380568B1 (en) | 2012-04-30 | 2012-04-30 | Novel use of extract of Pogongyeong |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130122435A KR20130122435A (en) | 2013-11-07 |
KR101380568B1 true KR101380568B1 (en) | 2014-04-02 |
Family
ID=49852233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120045772A KR101380568B1 (en) | 2012-04-30 | 2012-04-30 | Novel use of extract of Pogongyeong |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101380568B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102157141B1 (en) * | 2018-11-27 | 2020-09-17 | 주식회사 파미니티 | Compositions containing and natural clematis mandshurica extracts for improving cognitive function |
KR102172916B1 (en) * | 2018-12-07 | 2020-11-02 | 주식회사 파미니티 | Compositions containing silk peptide and natural extracts for improving cognitive function |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100814949B1 (en) | 2006-12-14 | 2008-03-19 | 인제대학교 산학협력단 | Composition comprising the extract of taraxacum mongolicum for treating and preventing diabetic complication and lipid metabolism disorder |
KR20090074337A (en) * | 2008-01-02 | 2009-07-07 | 인제대학교 산학협력단 | Composition for treating and preventing hypertension comprising the extract of taraxacum mongolicum |
US20110123639A1 (en) | 2009-11-26 | 2011-05-26 | Chan Agnes Sui-Yin | Compound for improving brain functioning and/or treatment of brain disorders |
-
2012
- 2012-04-30 KR KR1020120045772A patent/KR101380568B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100814949B1 (en) | 2006-12-14 | 2008-03-19 | 인제대학교 산학협력단 | Composition comprising the extract of taraxacum mongolicum for treating and preventing diabetic complication and lipid metabolism disorder |
KR20090074337A (en) * | 2008-01-02 | 2009-07-07 | 인제대학교 산학협력단 | Composition for treating and preventing hypertension comprising the extract of taraxacum mongolicum |
US20110123639A1 (en) | 2009-11-26 | 2011-05-26 | Chan Agnes Sui-Yin | Compound for improving brain functioning and/or treatment of brain disorders |
Non-Patent Citations (2)
Title |
---|
범진선, 원광대학교 박사학위논문, "포공영 기원 식물의 뇌 세포보호 활성 비교 연구", 2010년 2월 * |
범진선, 원광대학교 박사학위논문, "포공영 기원 식물의 뇌 세포보호 활성 비교 연구", 2010년 2월* |
Also Published As
Publication number | Publication date |
---|---|
KR20130122435A (en) | 2013-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101360109B1 (en) | Pharmaceutical Composition comprising spinosin for prevention and treatment of cognitive disorder | |
US11771726B2 (en) | Composition, containing Quisqualis indica extract, for preventing or treating prostatic hyperplasia | |
JP6803893B2 (en) | VCAM-1 expression inhibitor | |
KR101207781B1 (en) | A composition comprising the compound isolated from chrysanthyum indicum for preventing and treating cerebrovascular system involved depression | |
KR102227186B1 (en) | Composition comprising the extract of Belamcanda chinensis for preventing or treating neuro degenerative disease | |
KR20090118465A (en) | A composition comprising a radix extract of mountain cultivated ginseng as an active ingredient for preventing and treating brain disease | |
JP6735347B2 (en) | Composition for improving memory, which contains an extract of butterbur leaves | |
KR101793503B1 (en) | Composition for prevention or treatment of neurodegenerative diseases | |
KR20110005144A (en) | Pharmaceutical composition and health-food composition containing ginseng extracts having neuroprotective effects | |
KR101380568B1 (en) | Novel use of extract of Pogongyeong | |
KR101508395B1 (en) | Composition comprising the extract of Prunella vulgaris L for preventing and treating schizophrenia and amnesia | |
KR101228920B1 (en) | A composition comprising of a leaf extract of dendropanax morbifera for treating and preventing intestinal function disorder | |
KR20130122426A (en) | Novel use of extract of sasangja | |
KR101119410B1 (en) | Foeniculum vulgar extracts compositions for treating or preventing inflammatory diseases | |
KR100781581B1 (en) | Pharmaceutical composition comprising gomisin-? as an effective ingredient showing neuro-protective activity | |
KR101509056B1 (en) | Composition having brain function and congnition enhancing activity comprising ginseng mixed herbal extracts, ginsenoside Rg2 and ginsenoside F2 | |
KR101367885B1 (en) | A composition comprising the extract of combined herb of Panax ginseng and Vitis genus plant treating and preventing neuro-degenerative disease and enhancing memory power | |
KR101753057B1 (en) | Pharmaceutical composition for prevention or treatment of cognitive dysfunction or degenerative brain disease | |
KR100740566B1 (en) | A composition comprising phenylpropanoid compounds showing anxiolytic and memory improving activity | |
KR101194974B1 (en) | A composition comprising the extract of Crataegus pinnatifida treating and preventing neuro-degenerative disease | |
KR100886948B1 (en) | Composition comprising Nodakenin having neuronal cell-protecting activity for preventing and treating the degenerative brain disease | |
KR101725979B1 (en) | A composition of myrrh extracts for treating memory impairment | |
KR20190041350A (en) | Composition comprising extract of Panax ginseng and Liriope platyphylla for preventing or treating learning, cognition or memory disabilities | |
KR102054129B1 (en) | A composition comprising extracts of Safflower seed and Korean dandelion for preventing or treating cognitive dysfunction | |
US7824718B2 (en) | Extract of Dioscorea opposita thunb showing neuronal cell-protecting activity for treating memory loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170110 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180214 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20200115 Year of fee payment: 7 |